Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd., a leader in the Chinese medical aesthetics market, has successfully renewed its exclusive distribution agreement with Hugel for the botulinum toxin product Letybo until 2030. Letybo has gained significant market share in China, with sales surging by over 50% year-on-year in the first half of 2024. The company is confident that its strategic partnership with Hugel will further establish Letybo as a top brand in China and add value for shareholders.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
